{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:12:58Z","timestamp":1794931978943,"version":"4.9.1"},"reference-count":60,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","metabolismjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Metabolism"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.metabol.2024.155835","type":"journal-article","created":{"date-parts":[[2024,3,19]],"date-time":"2024-03-19T03:50:26Z","timestamp":1710820226000},"page":"155835","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":157,"special_numbering":"C","title":["Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges"],"prefix":"10.1016","volume":"154","author":[{"given":"Michail","family":"Kokkorakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chrysoula","family":"Boutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael A.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vasilios","family":"Kotsis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Loomba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun J.","family":"Sanyal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christos S.","family":"Mantzoros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.metabol.2024.155835_bb0005","first-page":"101","article-title":"Predictive models with the use of omics and supervised machine learning to diagnose non-alcoholic fatty liver disease: a \u201cnon-invasive alternative\u201d to liver biopsy?","author":"Katsiki","year":"2019","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155835_bb0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.metabol.2013.10.010","article-title":"Necessity for timely noninvasive diagnosis of nonalcoholic fatty liver disease","volume":"63","author":"Polyzos","year":"2014","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155835_bb0015","doi-asserted-by":"crossref","DOI":"10.1124\/pharmrev.123.001087","article-title":"Steatotic liver disease: pathophysiology and emerging pharmacotherapies","author":"Kokkorakis","year":"2024","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.metabol.2024.155835_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155664","article-title":"From non-alcoholic fatty liver disease (NAFLD) to steatotic liver disease (SLD): an ongoing journey towards refining the terminology for this prevalent metabolic condition and unmet clinical need","volume":"147","author":"Kokkorakis","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155835_bb0025","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.metabol.2024.155835_bb0030","first-page":"134","article-title":"Time to transition from a negative nomenclature describing what NAFLD is not, to a novel, pathophysiology-based, umbrella classification of fatty liver disease (FLD)","author":"Valenzuela-Vallejo","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155835_bb0035","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3390\/metabo11020073","article-title":"Glucagon-like peptide-1 receptor agonists for treatment of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: an updated meta-analysis of randomized controlled trials","volume":"11","author":"Mantovani","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.metabol.2024.155835_bb0040","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.metabol.2024.155835_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155462","article-title":"Effects of semaglutide on metabolic syndrome parameters in non-diabetics: a meta-analysis of randomized controlled trials","volume":"142","author":"Aggarwal","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155835_bb0050","first-page":"148","article-title":"Pharmacotherapy before and after bariatric surgery","author":"Alabduljabbar","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155835_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155741","article-title":"Advances in obesity pharmacotherapy; learning from metabolic surgery and beyond","volume":"151","author":"Tsilingiris","year":"2024","journal-title":"Metab - Clin Exp"},{"key":"10.1016\/j.metabol.2024.155835_bb0060","first-page":"142","article-title":"Advances in physiology, design and development of novel medications changing the landscape of obesity pharmacotherapy","author":"Chakhtoura","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155835_bb0065","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.155835_bb0070","series-title":"Anti-atherosclerotic effects of the glucagon-like peptide-1 (GLP-1) based therapies in patients with type 2 Diabetes Mellitus: a meta-analysis OPEN","author":"Song","year":"2015"},{"key":"10.1016\/j.metabol.2024.155835_bb0075","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1002\/ueg2.12124","article-title":"Impact of thyroid disorders on the incidence of non-alcoholic fatty liver disease in Germany","volume":"9","author":"Labenz","year":"2021","journal-title":"United Eur Gastroenterol J"},{"key":"10.1016\/j.metabol.2024.155835_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154925","article-title":"Insights into the molecular targets and emerging pharmacotherapeutic interventions for nonalcoholic fatty liver disease","volume":"126","author":"Negi","year":"2022","journal-title":"Metab - Clin Exp"},{"key":"10.1016\/j.metabol.2024.155835_bb0085","first-page":"44","article-title":"Thyroid function, adipokines and mitokines in metabolic dysfunction-associated steatohepatitis: a multi-centre biopsy-based observational study","author":"Kouvari","year":"2024","journal-title":"Liver Int"},{"key":"10.1016\/j.metabol.2024.155835_bb0090","first-page":"134","article-title":"Comprehensive molecular mechanisms and clinical therapy in nonalcoholic steatohepatitis: an overview and current perspectives","author":"Yan","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155835_bb0095","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1210\/jc.2016-1300","article-title":"Thyroid function and the risk of nonalcoholic fatty liver disease: the Rotterdam Study","volume":"101","author":"Bano","year":"2016","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.metabol.2024.155835_bb0100","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.dld.2022.06.021","article-title":"Sensitivity to thyroid hormones is associated with advanced fibrosis in euthyroid patients with non-alcoholic fatty liver disease: a cross-sectional study","volume":"55","author":"Li","year":"2023","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.metabol.2024.155835_bb0105","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1089\/thy.2018.0664","article-title":"Nonalcoholic fatty liver disease and hypercholesterolemia: roles of thyroid hormones, metabolites, and agonists","volume":"29","author":"Sinha","year":"2019","journal-title":"Thyroid"},{"key":"10.1016\/j.metabol.2024.155835_bb0110","doi-asserted-by":"crossref","first-page":"114","DOI":"10.4254\/wjh.v6.i3.114","article-title":"Thyroid hormone analogues and derivatives: actions in fatty liver","volume":"6","author":"Coppola","year":"2014","journal-title":"World J Hepatol"},{"key":"10.1016\/j.metabol.2024.155835_bb0115","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1097\/MOL.0b013e3283402e9c","article-title":"Lipid lowering with thyroid hormone and thyromimetics","volume":"21","author":"Angelin","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.metabol.2024.155835_bb0120","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1056\/NEJMoa2309000","article-title":"A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis","volume":"390","author":"Harrison","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.155835_bb0125","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1152\/ajpendo.00506.2002","article-title":"Spared bone mass in rats treated with thyroid hormone receptor TR\u03b2-selective compound GC-1","volume":"285","author":"Freitas","year":"2003","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.metabol.2024.155835_bb0130","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0905633","article-title":"Use of the thyroid hormone analogue eprotirome in statin-treated dyslipidemia","volume":"362","author":"Ladenson","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.metabol.2024.155835_bb0140","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet (London, England)"},{"key":"10.1016\/j.metabol.2024.155835_bb0145","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1002\/hep4.1657","article-title":"Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH","volume":"5","author":"Harrison","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.metabol.2024.155835_bb0150","first-page":"23","article-title":"Cell-specific transport and thyroid hormone receptor isoform selectivity account for hepatocyte-targeted thyromimetic action of MGL-3196","author":"H\u00f6nes","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.metabol.2024.155835_bb0155","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1021\/jm4019299","volume":"57","author":"Kelly","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.metabol.2024.155835_bb0160","doi-asserted-by":"crossref","first-page":"2919","DOI":"10.1038\/s41591-023-02603-1","article-title":"Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial","volume":"29","author":"Harrison","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.metabol.2024.155835_bb0165","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1016\/j.cgh.2021.07.039","article-title":"Hepatic fat reduction due to resmetirom in patients with nonalcoholic steatohepatitis is associated with improvement of quality of life","volume":"20","author":"Younossi","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.155835_bb0170","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1053\/j.gastro.2016.03.005","article-title":"Contribution of alcoholic and nonalcoholic fatty liver disease to the burden of liver-related morbidity and mortality","volume":"150","author":"Younossi","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.metabol.2024.155835_bb0175","doi-asserted-by":"crossref","first-page":"60","DOI":"10.17925\/EE.2023.19.1.60","article-title":"Resmetirom: an orally administered, smallmolecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis","volume":"19","author":"Karim","year":"2023","journal-title":"TouchREVIEWS Endocrinol"},{"key":"10.1016\/j.metabol.2024.155835_bb0180","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1161\/01.CIR.0000023921.93743.89","article-title":"Mitochondrial integrity and function in atherogenesis","volume":"106","author":"Ballinger","year":"2002","journal-title":"Circulation"},{"issue":"15","key":"10.1016\/j.metabol.2024.155835_bb0185","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40265-017-0791-4","article-title":"Potential role of thyroid receptor \u03b2 agonists in the treatment of hyperlipidemia","volume":"77","author":"Jakobsson","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.metabol.2024.155835_bb0195","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1080\/13696998.2022.2026702","article-title":"Cost-effectiveness and potential value of pharmaceutical treatment of nonalcoholic fatty liver disease","volume":"25","author":"Rustgi","year":"2022","journal-title":"J Med Econ"},{"key":"10.1016\/j.metabol.2024.155835_bb0200","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/S2468-1253(24)00049-9","article-title":"Resmetirom for NASH: balancing promise and prudence","volume":"9","author":"The Lancet Gastroenterology & Hepatology","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.metabol.2024.155835_bb0210","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1007\/s00125-016-3944-1","article-title":"Diagnosis of non-alcoholic fatty liver disease (NAFLD)","volume":"59","author":"Yki-J\u00e4rvinen","year":"2016","journal-title":"Diabetologia"},{"key":"10.1016\/j.metabol.2024.155835_bb0215","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/hep.22572","article-title":"Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist","volume":"49","author":"Cable","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.metabol.2024.155835_bb0220","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1016\/S0735-1097(16)31933-7","article-title":"A phase 1 randomized, double-blind, placebo-controlled, multiple ascending dose study to evaluate safety, tolerability and pharmacokinetics of the liver-selective TR-beta agonist VK2809 (MB07811) in hypercholesterolemic subjects","volume":"67","author":"Lian","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.metabol.2024.155835_bb0225","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1089\/thy.2020.0071","article-title":"Thyroid hormone analogues: an update","volume":"30","author":"Zucchi","year":"2020","journal-title":"Thyroid"},{"key":"10.1016\/j.metabol.2024.155835_bb0235","unstructured":"Charfi H, Pinquier JL, Massetto B, Le K, Westland C, Gupta K, et al. Safety and pharmacokinetics (PK) of single and multiple ascending oral doses of ALG-055009, a thyroid hormone receptor beta agonist, for the treatment of non-alcoholic steatohepatitis (NASH), in healthy volunteers and subjects with hyperlipidaemia. n.d."},{"key":"10.1016\/j.metabol.2024.155835_bb0240","author":"Charfi"},{"key":"10.1016\/j.metabol.2024.155835_bb0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2021.154779","article-title":"The progression and regression of metabolic dysfunction-associated fatty liver disease are associated with the development of subclinical atherosclerosis: a prospective analysis","volume":"120","author":"Liu","year":"2021","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.metabol.2024.155835_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155220","article-title":"Nonalcoholic fatty liver disease and cardiovascular diseases: a Mendelian randomization study","volume":"133","author":"Peng","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155835_bb0260","first-page":"147","article-title":"Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: results from a large multi-center study","author":"Kouvari","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155835_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2023.155689","article-title":"Milestones in the journey towards addressing obesity; past trials and triumphs, recent breakthroughs, and an exciting future in the era of emerging effective medical therapies and integration of effective medical therapies with metabolic surgery","volume":"148","author":"Kokkorakis","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155835_bb0270","first-page":"203","article-title":"The first external validation of the Dallas steatosis index in biopsy-proven non-alcoholic fatty liver disease: a multicenter study","author":"Kouvari","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.metabol.2024.155835_bb0275","first-page":"133","article-title":"Association of fatty liver index with all-cause and disease-specific mortality: a nationwide cohort study","author":"Chung","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155835_bb0280","first-page":"119","article-title":"Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk","author":"Muzurovi\u0107","year":"2021","journal-title":"Metabolism"},{"issue":"79","key":"10.1016\/j.metabol.2024.155835_bb0285","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1161\/HYPERTENSIONAHA.122.17982","article-title":"Nonalcoholic fatty liver disease and cardiovascular disease: a review of shared cardiometabolic risk factors","author":"Muzurovi\u0107","year":"2022","journal-title":"Hypertens (Dallas, Tex 1979)"},{"key":"10.1016\/j.metabol.2024.155835_bb0290","first-page":"149","article-title":"Recent research advances in metabolism, clinical and experimental","author":"Boutari","year":"2023","journal-title":"Metab - Clin Exp"},{"key":"10.1016\/j.metabol.2024.155835_bb0295","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155800","article-title":"Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: a community-dwelling cohort study with 20-year follow-up","volume":"153","author":"Choe","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155835_bb0300","first-page":"136","article-title":"Recent guidelines for non-alcoholic fatty liver disease (NAFLD)\/ fatty liver disease (FLD): are they already outdated and in need of supplementation?","author":"Valenzuela-Vallejo","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155835_bb0305","first-page":"128","article-title":"The presence of NAFLD influences the transition of metabolically healthy to metabolically unhealthy obesity and the ten-year cardiovascular disease risk: a population-based cohort study","author":"Kouvari","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155835_bb0310","first-page":"146","article-title":"Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States","author":"Golabi","year":"2023","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155835_bb0315","first-page":"115","article-title":"MAFLD and risk of CKD","author":"Sun","year":"2021","journal-title":"Metabolism"},{"key":"10.1016\/j.metabol.2024.155835_bb0320","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.eprac.2022.03.010","volume":"28","author":"Cusi","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.metabol.2024.155835_bb0325","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1053\/j.gastro.2023.06.013","article-title":"AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease: expert review","volume":"165","author":"Wattacheril","year":"2023","journal-title":"Gastroenterology"}],"container-title":["Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524000611?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0026049524000611?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T04:35:45Z","timestamp":1758429345000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0026049524000611"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":60,"alternative-id":["S0026049524000611"],"URL":"https:\/\/doi.org\/10.1016\/j.metabol.2024.155835","relation":{},"ISSN":["0026-0495"],"issn-type":[{"value":"0026-0495","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges","name":"articletitle","label":"Article Title"},{"value":"Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.metabol.2024.155835","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"155835"}}